Citigroup analyst Joanne Wuensch maintains Intuitive Surgical (NASDAQ:ISRG) with a Buy and raises the price target from $428 to $462.
Citigroup analyst Joanne Wuensch maintains Intuitive Surgical (NASDAQ:ISRG) with a Buy Read Post »
Citigroup analyst Andrew Baum maintains Eli Lilly and Co with a Buy and raises the price target from $675 to $895.
Citigroup analyst Andrew Baum maintains Eli Lilly and Co with a Buy Read Post »
RBC Capital analyst Luca Issi reiterates Moderna with a Outperform and maintains $125 price target.
RBC Capital analyst Luca Issi reiterates Moderna with a Outperform Read Post »
Amedisys’ (AMED) acquisition by UnitedHealth Group’s (UNH) Optum unit is expected to be completed despite unconfirmed reports of a possible antitrust investigation by the US Department of Justice, RBC Capital Markets said in a note Monday. The brokerage said it expects the combination of Amedisys and Optum health services to create the largest home health platform in the US with about 10% market share. “We continue to believe that the Optum/AMED deal will close given strong precedent for carriers operating home health assets and the high fragmentation across the home care sector, even pro forma for the combination,” RBC said. RBC raised its price target for Amedisys to $100 from $97, factoring in the upside potential from a deal, and maintained its outperform rating on the stock. However, it also provided a downside valuation of $74 in a potential deal-break scenario, reflecting “a discount to peers and a slight discount
Truist Securities analyst Robyn Karnauskas reiterates Eli Lilly and Co with a Buy and maintains $850 price target.
Truist Securities analyst Robyn Karnauskas reiterates Eli Lilly and Co with a Buy Read Post »
By Elena Vardon Pfizer plans to sell a stake in Haleon currently valued at around 2 billion pounds ($2.55 billion), trimming its ownership in the consumer-healthcare business for the first time since its listing. The pharmaceutical giant intends to reduce its stake in Haleon to 24% from 32% currently, Haleon said Monday. With the move, Pfizer follows U.K. drugmaker GSK, which has been offloading its initial 12.9% shareholding in the company in recent months and now owns a 4.2% stake. This comes at a time of intense merger-and-acquisition activity in the pharmaceutical industry, which has seen big companies snapping up smaller biotechnology businesses. Haleon–which houses Sensodyne toothpaste and Aquafresh mouthwash as well as over-the-counter medicines Panadol and Advil–also agreed to buy back shares valued at GBP315 million from Pfizer at the same price as the public offer’s. The offer price will be determined via an accelerated bookbuild offering process which
Pfizer to Cut Stake in Haleon Read Post »
JP Morgan analyst Chris Schott maintains Eli Lilly and Co with a Overweight and raises the price target from $775 to $850.
JP Morgan analyst Chris Schott maintains Eli Lilly and Co with a Overweight Read Post »
Eli Lilly and Company’s (LLY) phase 3 clinical trial of tirzepatide in obstructive sleep apnea is likely to miss consensus expectations given the gender imbalance in the study, but could still meet study endpoints, UBS said in a note Thursday. The investment bank said it expects a 12% to 14% weight loss and a 30% to 37% reduction in the apnea-hypopnea index, or AHI, compared with the Street consensus for 20% weight loss and over 50% AHI reduction from baseline. “We think gender imbalances are the main culprit as it’s well-documented females disproportionately lose more weight than males,” UBS said in the note. Males make up 70% of the trial participants, while females account for the remaining 30%, according to the note. The firm maintained its buy rating on the company’s stock with a 12-month price target of $910.
Intuitive (ISRG) late Thursday said its next-generation robotic surgical system given 510(k) clearance by the US Food and Drug Administration for its da Vinci 5 multiport robotic system. The new da Vinci 5 systems includes more than 150 enhancements from its predecessor devices, including improved accuracy and precision, 3D display and image processing and first-of-its-kind “force-sensing” tools. Intuitive is expecting da Vinci 5 will be first available for a handful of US customers who collaborated with the company during its development, providing additional data about the new device ahead of a wider release. Intuitive shares were 3% higher in after-hours activity.
Intuitive Da Vinci 5 Robotic Systems Receives FDA Clearance — Shares Rising After Hours Read Post »
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We add Eli Lily and Company (LLY) to CFRA’s High-Quality Capital Appreciation Portfolio. LLY is one of the largest U.S. drug makers in terms of revenue and is a leading developer of drugs in a wide range of therapeutic areas such as endocrinology, which includes a diabetes drug portfolio that generates more than half of its total revenue. We are increasingly optimistic on LLY’s many ongoing efforts, including late-stage therapies such as donanemab (for Alzheimer’s disease), pirtobrutinib (for certain forms of leukemia and lymphoma), and tirzepatide (for sleep apnea and cardiology). Such innovation could complement LLY’s 10 key current drugs, which represent the majority of LLY’s total sales. LLY replaces CVS Health Corporation, which was downgraded to a Hold recommendation.
CFRA Adds Eli Lilly To The High-quality Capital Appreciation Portfolio Read Post »
Moderna Exec Says Co Could Consider Partnerships And Project Financing As Options To Fund Pipeline Programs Beyond 2026.
Oppenheimer analyst Hartaj Singh cites Moderna’s share move to a notice on the U.S. clinical trials register that the company, along with Merck MRK.N, will begin testing their vaccine combination for the treatment of a form of skin cancer called cutaneous squamous cell carcinoma (CSCC) CSCC is the second-most common form of skin cancer in the U.S. Merck’s immunotherapy Keytruda along with Moderna’s MRNA-based vaccine are also being evaluated for the treatment of melanoma and non-small cell lung cancer Analysts at Jefferies say this being the third late-stage study for the vaccine combination speaks to continued confidence in a broad program
“Moderna Rises On New Skin Cancer Treatment Trial With Merck, Analysts Say” – Reuters Read Post »